Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Fig. 1

Assessment of the strength of interleukin-6/phosphorylated STAT3 (IL-6/pSTAT3) signal inhibition. a Representative intracellular staining pattern of pSTAT3 in CD3+ cells, CD3 + CD4− T cells and CD3 + CD4+ T cells by flow cytometry (IL-6 stimulation = 100 ng/ml). b Measurement of the proportion of pSTAT3-positive CD4+ T cells with exogenous IL-6 stimulation (0, 0.1, 1, 10, 100 ng/ml) in each group of patients administered either tocilizumab (TCZ) at different intervals or methotrexate (MTX). Open histograms represent isotype control antibody staining and filled plots represent anti-pSTAT3 antibody staining

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us